A recent paper published by the American Enterprise Institute revealed that the net prices for the new obesity drugs are just a fraction of the published annual list prices.
And while the drugs’ prices remain out of reach for many, economists anticipate they will soon be driven down.
More than a dozen companies are developing obesity drugs.
As they enter the market, greater choice is expected to make prices plummet, as has happened with other expensive drugs.
Those revenues are based on the net prices.
Persons:
”, Jalpa Doshi, Ippolito, Joseph F, Levy
Organizations:
American Enterprise Institute, University of Pennsylvania, Investors, Novo Nordisk, Johns Hopkins Bloomberg School of Public Health, Health
Locations:
Denmark, Novo